• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells
Tez

Tez
Open Access
Kaynak :
YÖK Tez Merkezi
Yazar(lar) :
AYSUN ADAN GÖKBULUT
Konu :
Biyoloji
Yıl :
2015
Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells and CML for the first time. There were decreases in the viability/proliferation of K562 and HL60 cells treated with fisetin, hesperetin and vitexin. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin and hesperetin treatment while providing
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Türkçe Özet :
Fisetin, hesperetin ve viteksin bitkilerde yaygın olarak bulunan flavonoid'lerdir. Bu çalışmada fisetin, hesperetin ve viteksinin HL60 APL and K562 KML hücreleri üzerindeki sitotoksik, apoptotik ve sitostatik etkilerinin incelenmesi amaçlanmaktadır. Bu üç flavonoid'in APL ve KML üzerindeki etkilerini gösteren herhangi bir çalışma bulunmamaktadır. Bu çalışmada ayrıca tüm genom mikroçip analizi yapılarak fisetin ve hesperetin ile muamele edilen APL ve KML hücrelerinde değişime uğrayan genler ve sinyal iletim yollarının belirlenmesi amaçlanmıştır. Özet olarak, söz konusu flavonoid lerin APL ve KML hücreleri üzerindeki etkilerinin moleküler mekanizmaları ve global gen ifadesindeki değişikliklerin ilk defa gösterilmesi amaçlanmıştır. Fisetin, hesperetin ve viteksin ile muamele edilen K562 KML ve HL60 APL hücrelerinde doza ve zamana bağımlı olarak hücre canlılığında bir azalma olduğu gösterilmiştir. Her iki hücre tipinde apoptozun tetiklenmesinde en etkili ajanın fisetin olduğu saptanmıştır. Ayrıca, fisetin, hesperetin ve viteksinin her iki hücre tipinde hücre döngüsünün farklı safhaları üzerinde etkili olduğu dolayısyla sitostatik etkiye sahip olduğu gösterilmiştir. Sonuç olarak, fisetin ve hesperetinin hücre çoğalmasını inhibe etmeleri, apoptozu tetiklemeleri ve hücre döngüsünün çeşitli safhalarında tutulmalara neden olmalarından dolayı hem KML hem de APL tedavisinde terapötik potansiyellerinin olabileceği düşünülmektedir. Ayrıca, tüm genom mikroçip analizinden elde edilen sonuçlar fisetin ve hesperetin muamelesi sonucu etkilenen biyolojik yolakların ve bu yolaklarda görev alan molekülleri kodlayan genlerin tanımlanmasını sağlamıştır. Bu genlerin hedeflenerek KML ve APL tedavisinde kullanılabileceği düşünülmektedir.
İngilizce Başlık : Fisetin, hesperetin ve viteksin'in kronik miyeloid lösemi ve akut miyeloid lösemi hücreleri üzerine terapötik potansiyelleri
İngilizce Özet :
Fisetin, hesperetin and vitexin are plant-derived flavonoids. This thesis study aims to investigate therapeutic potentials of them on human HL60 APL and K562 CML cells since there are no studies on these cells. The effects of these compounds on APL and CML cells have been considered in terms of cytotoxicity, apoptosis and cell cycle progression. In this study, genome-wide microarray analysis has been also performed for APL and CML cells to identify the genes and networks that are responsible for fisetin and hesperetin-induced effects. In summary, we intented to explain the molecular mechanisms and global gene expression patterns related with the effects of these flavonoids on both APL and CML for the first time. There were decreases in the viability/proliferation of K562 and HL60 cells treated with fisetin, hesperetin and vitexin. Fisetin was the most effective flavonoid for the induction of apoptosis in both cells. Fisetin, hesperetin and vitexin have been found to affect cell cycle progression at different phases of the cell cycle in both CML and AML cells, thus having cytostatic effects. In conclusion, the results of this study indicated that especially fisetin and hesperetin may have therapeutic potential in APL and CML cells due to induction of apoptosis, inhibition of cell proliferation and cell cyle arrest. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin and hesperetin treatment while providing a proof of principle for identifying candidate genes that might be targeted for CML and APL therapy.
Anahtar Kelimeler : Kanser hücreleri, Lösemi, Flavonlar
2
Childhood Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Treatment Options in Oncology
Yazar(lar) :
Jeffrey E. Rubnitz
Konu :
Pharmacology (medical), Oncology
Yıl :
2008
Childhood Acute Myeloid Leukemia Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia Instead, advances in the treatment of children with AML will require a greater understanding of the biology of the disease, with particular attention to More important, we must develop alternative treatment approaches, such as agents that target specific leukemia-associated abnormalities and agents that Current Treatment Options in Oncology Acute Myeloid Leukemia Acute Myeloid Leukemia Patient
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy. Instead, advances in the treatment of children with AML will require a greater understanding of the biology of the disease, with particular attention to the genetic abnormalities underlying leukemogenesis and drug resistance. Future clinical trials should include refined risk-directed therapy based on the genetics of the leukemic blasts and the patient’s response to therapy. More important, we must develop alternative treatment approaches, such as agents that target specific leukemia-associated abnormalities and agents that selectively eradicate leukemic stem cells.
DOI : 10.1007/s11864-008-0059-z
Anahtar Kelimeler : Acute Myeloid Leukemia, Minimal Residual Disease, Acute Myeloid Leukemia Patient, Gemtuzumab Ozogamicin, Clofarabine
ISSN: 1527-2729 1534-6277
Sayı: 1
Cilt: 9
Sayfa: 95-105
3
Acute myeloid leukemia
Kitap Bölümü

Kitap Bölümü
Kaynak 1:
Wiley Online Library
Kaynak 2:
Wiley Online Library
Kaynak 3:
Wiley Online Library
Kaynak 4:
Wiley Online Library
Dergi:
Clinical Manual of Blood and Bone Marrow Transplantation
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Hillard M. Lazarus , Masumi Ueda
Yıl :
2017
Acute myeloid leukemia This chapter summarizes the currently available data, and presents recommendations regarding if and when to pursue a transplant for persons with acute myeloid leukemia (AML), the optimal conditioning regimen, the graft type, and use of alternative donors. of donor cells and be minimally toxic to the recipient. Clinical Manual of Blood and Bone Marrow Transplantation
Tam Metin
Kaydet Alıntıla
This chapter summarizes the currently available data, and presents recommendations regarding if and when to pursue a transplant for persons with acute myeloid leukemia (AML), the optimal conditioning regimen, the graft type, and use of alternative donors. Several meta‐analyses compared results of allogeneic hematopoietic cell transplantation (HCT) to chemotherapy alone or autologous HCT as post‐remission therapy in AML. These trials compared outcomes based on donor availability, or “biologic randomization”. Data from reports of measurable residual disease (MRD) testing in first remission AML patients indicate a correlation with detecting MRD pre‐transplant and relapse risk. MRD was tested after two cycles of induction chemotherapy. Bone marrow cells, blood cells, or umbilical cord blood cells are used for AML allotransplants. The ideal conditioning regimen for AML allogeneic transplantation should eliminate leukemia cells, provide enough immunosuppression to allow engraftment of donor cells and be minimally toxic to the recipient.
DOI : 10.1002/9781119095491.ch11
ISBN:9781119095453
Sayfa: 89-96
4
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
JSTOR
Dergi:
Proceedings of the National Academy of Sciences of the United States of America
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Shuangli Mi , Jun Lu , Miao Sun , Zejuan Li , Hao Zhang , Mary Beth Neilly , Yungui Wang , Zhijian Qian , Jie Jin , Yanming Zhang , Stefan K. Bohlander , Michelle M. Le Beau , Richard A. Larson , Todd R. Golub , Janet D. Rowley , Jianjun Chen
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2007
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, whereas acute myeloid leukemia (AML) is the most common acute leukemia in adults To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment, we performed a large-scale The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute leukemia samples covering
Yayıncı Web Sitesi
Kaydet Alıntıla
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, whereas acute myeloid leukemia (AML) is the most common acute leukemia in adults. In general, ALL has a better prognosis than AML. To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment, we performed a large-scale genome-wide microRNA (miRNA, miR) expression profiling assay and identified 27 miRNAs that are differentially expressed between ALL and AML. Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML. The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute leukemia samples covering most of the common cytogenetic subtypes, along with 10 normal control samples. Furthermore, we found that overexpression of miR-128 in ALL was at least partly associated with promoter hypomethylation and not with an amplification of its genomic locus. Taken together, we showed that expression signatures of as few as two miRNAs could accurately discriminate ALL from AML, and that epigenetic regulation might play an important role in the regulation of expression of miRNAs in acute leukemias.
Cilt: 104
Sayı: 50
Sayfa: pp. 19971-19976
Yayın Tarihi: 2007-12-11
ISSN: 0027-8424
5
Acute kidney injury and childhood acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Pediatric Nephrology
Yazar(lar) :
Chompoonut Limratchapong , Praewa Sophark , Prayong Vachvanichsanong , Edward B. McNeil , Thirachit Chotsampancharoen
Konu :
Nephrology, Pediatrics, Perinatology and Child Health
Yıl :
2022
Acute kidney injury and childhood acute myeloid leukemia Acute kidney injury (AKI) appears to be particularly common in children with acute myeloid leukemia (AML), although the epidemiology data on this patient The objective of this study was to assess the prevalence and factors associated with AKI in childhood AML during chemotherapy treatment. Age ≥ 10 years at diagnosis, impaired kidney function before treatment, and septic shock were strongly associated with AKI. Nephrology,Pediatrics, Perinatology and Child Health Acute kidney injury Childhood acute myeloid leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute kidney injury (AKI) appears to be particularly common in children with acute myeloid leukemia (AML), although the epidemiology data on this patient population is sparse. The objective of this study was to assess the prevalence and factors associated with AKI in childhood AML during chemotherapy treatment. The medical records of 112 children aged under 15 years diagnosed with AML who received chemotherapy in a major tertiary-care referral center in southern Thailand were reviewed. Logistic regression was used to identify factors associated with AKI. Fifty-six (50%) children had AKI events. The median time from AML diagnosis to the first AKI was 29.5 days (interquartile range: 11.0–92.8) and the median follow-up time was 10.9 months (interquartile range: 3.6–31.1). Age at diagnosis ≥ 10 years (OR 2.75, 95% CI 1.09–6.93), glomerular filtration rate < 90 mL/min/1.73 m2 at AML diagnosis (OR 7.58, 95% CI 1.89–30.5), and septic shock (OR 22.0, 95% CI 4.63–104.3) were independently associated with AKI. Childhood AML has a high rate of kidney injury with 50% having AKI. Age ≥ 10 years at diagnosis, impaired kidney function before treatment, and septic shock were strongly associated with AKI. A higher resolution version of the is available as Supplementary information.
DOI : 10.1007/s00467-022-05506-4
Anahtar Kelimeler : Acute kidney injury, Childhood acute myeloid leukemia, Oncology, Risk factor
ISSN: 0931-041X 1432-198X
6
Molecular Emergence of Acute Myeloid Leukemia during Treatment for Acute Lymphoblastic Leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
JSTOR
Dergi:
Proceedings of the National Academy of Sciences of the United States of America
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Javier G. Blanco , Thierry Dervieux , Mathew J. Edick , Perdeep K. Mehta , Jeffrey E. Rubnitz , Sheila Shurtleff , Susana C. Raimondi , Frederick G. Behm , Ching-Hon Pui , Mary V. Relling
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2001
Molecular Emergence of Acute Myeloid Leukemia during Treatment for Acute Lymphoblastic Leukemia Therapy-related acute myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a child who developed t-AML with a t(11;19) (q23;p13.3) during treatment for acute lymphoblastic leukemia (ALL).
Yayıncı Web Sitesi
Kaydet Alıntıla
Therapy-related acute myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a child who developed t-AML with a t(11;19) (q23;p13.3) during treatment for acute lymphoblastic leukemia (ALL). The MLL-ENL and the reciprocal ENL-MLL genomic fusions and their chimeric transcripts were characterized from samples collected at the time of t-AML diagnosis. We used PCR with patient-specific genomic primers to establish the emergence of the MLL-ENL fusion in serially obtained DNA samples. The MLL-ENL fusion was not detectable in bone marrow at the time of ALL diagnosis or after 2 months of chemotherapy (frequency <8.3 × 10-7 cells-1). The genomic fusion was first detected in bone marrow after 6 months of treatment at a frequency of one in 4,000 mononuclear bone marrow cells; the frequency was one in 70 cells after 20 months of therapy. At the first detection of MLL-ENL, the only topoisomerase II inhibitors the patient had received were one dose of daunorubicin and two doses of etoposide. The MLL-ENL fusion was not detectable in blood at the time of ALL diagnosis or after 0.7, 2, 8, 10, and 12 months of therapy but was detectable in blood at 16 months (one in 2.3 × 104 cells). Recombinogenic Alu sequences bracketed the breakpoints in both fusions. These data indicate that the malignant clone was not present before therapy, arose early during chemotherapy, and was able to proliferate even during exposure to antileukemic therapy.
Cilt: 98
Sayı: 18
Sayfa: pp. 10338-10343
Yayın Tarihi: 2001-08-28
ISSN: 0027-8424
7
Characterization of MYC expression in gefitinib versus Acute Myeloid Leukemia reveals novel therapeutic targets
Konferans Bildirileri

Konferans Bildirileri
Kaynak :
IEEE Xplore
Yazar(lar) :
James F. Courage , Saurabh Gupta , Yufeng Wang
Konu :
Bioengineering, Computing and Processing
Yıl :
2007
Characterization of MYC expression in gefitinib versus Acute Myeloid Leukemia reveals novel therapeutic targets We conducted gene expression profiling and pathway analysis of microarray data generated from a gefitinib versus M4-AML study. findings indicate that a therapeutic reduction of the human v-Myc oncoprotein correlated to molecular reversal of cell transformation within 24 hours of treatment These targets, Src and Jnk3, demonstrated strong interactions with gefitinib in small molecule/tyrosine kinase binding assays and have proven critical Bioengineering,Computing and Processing 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering Medical treatment acute myeloid leukemia Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
We conducted gene expression profiling and pathway analysis of microarray data generated from a gefitinib versus M4-AML study. Our findings indicate that a therapeutic reduction of the human v-Myc oncoprotein correlated to molecular reversal of cell transformation within 24 hours of treatment. We analyzed the known efficacies of gefitinib and were able to identify bona fide gefitinib targets in the PDGFR pathway that we believe to be responsible for cell rescue. These targets, Src and Jnk3, demonstrated strong interactions with gefitinib in small molecule/tyrosine kinase binding assays and have proven critical to MYC induction in gene inhibition assays.
DOI : 10.1109/bibe.2007.4375637
Anahtar Kelimeler : Cancer, Medical treatment, Drugs, Humans, Amino acids, Bones, White blood cells, Hemorrhaging, Gene expression, Data analysis, biochemistry, blood, cellular biophysics, diseases, drugs, enzymes, genetics, medical computing, microorganisms, molecular biophysics, MYC expression, myelocytomatosis viral oncogene homolog, gefitinib, acute myeloid leukemia, therapeutic targets, gene expression profiling, pathway analysis, microarray data, oncoprotein, cell transformation, tyrosine kinase, binding assays, gene inhibition assays, Microarray, MYC, Gefitinib, Acute Myeloid Leukemia, SRC, JNK3, P38
8
Evaluation of metabolite variation between acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines via triple quadrupole LC-MS
Tez

Tez
Open Access
Kaynak :
YÖK Tez Merkezi
Yazar(lar) :
CEREN PEKŞEN
Konu :
Biyoteknoloji
Yıl :
2019
Evaluation of metabolite variation between acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines via triple quadrupole LC-MS While lymphatic leukemia, originate from the lymphoid cell line, acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) originate from the myeloid Acute lymphoblastic leukemia (ALL), on the other hand, is caused by abnormally uncontrolled and excessive proliferation of lymphoblasts. ALL is responsible for 80% of childhood leukemia and is common between 3-7 years of age.
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Türkçe Özet :
Hematolojik kanserlerin iki kökeni vardır: miyeloid ve lenfoid. Lenfatik lösemi, len-foid hücre hattından, akut miyeloid lösemi (AML) ve kronik miyeloid lösemi (KML)ise miyeloid hücre hattından kaynaklanır.KML, granülosit kanseridir ve bu hastalıkta, granülositlerin yanı sıra, trombosit ola-rak adlandırdı ̆gımız kanın pıhtıla ̧smasına neden olan hücre sayısı kanda artabilir.KML'de, hastalı ̆gın önemli bir belirteci olarak kabul gören, kan hücrelerinde kro-mozom 22'de yapısal bir de ̆gi ̧sikli ̆gin meydana geldi ̆gi, genetik bir anormallik olan"Philadelphia kromozomu" görülmektedir. Akut lenfoblastik lösemi (ALL) ise anor-mal kontrolsüz ve a ̧sırı lenfoblast proliferasyonundan kaynaklanır. ALL, çocukluklösemisinin %80'inden sorumludur ve 3-7 ya ̧s aralı ̆gındaki çocuklarda sık rastlanır.Yeti ̧skinlerde de görülebilir ve tüm yeti ̧skin lösemilerinin %20'sini olusturur. ̇Ilginçbir ̧sekilde, blast fazına (BF) ula ̧smı ̧s KML'nin akut lösemiye dönüsebilecegi kaydedilmi ̧stir. Hangi mutasyonların bu dönü ̧süme neden oldu ̆gu bilinmemektedir. Tüm lösemi alt tipleri kemik ili ̆ginden kaynaklandıgı için, lösemi tiplerinin te ̧shisinde"altın standart" invaziv kemik ili ̆gi biyopsisi ile genetik testlerdir, ancak iyile ̧sme süreci vardır ve özellikle çocuklar üzerinde psikolojik etkileri olabilir. Son zamanlardalösemide erken te ̧shiste yardımcı olabilecek non-invaziv ve hızlı yöntemler ara ̧stırılmaktadır. Kemik ili ̆gi biyopsisi ile elde edilen hücreler, sitogenetik analiz ile kromo-zomal anormallikler açısından da incelenmektedir.Bu çalı ̧smada Jurkat (ALL) ve K562 (BF-KML) hücre hatlarının metabolik farklılık-ları HPLC-MS aracılı ̆gıyla de ̆gerlendirildi. Her bir hücre hattındaki metabolitlerinmiktarı hakkında fikir edinmek için kantitatif ve yarı-kantitatif çalı ̧smalar yapıldı.Otantik standartların kullanımıyla laktik asit ve sitrik asit konsantrasyonları ölçüldükten sonra, her iki hücre hattında da toplu taramalar yapıldı, ve dönü ̧süm sırasında esasolarak etkilenen metabolizmaların tirozin, arginin ve prolin, ve glutatyon metabolizmaları oldu ̆gu görüldü. Ardından, örneklerde bu ilgili yolakları indike eden metabolitlerinin varlı ̆gı tarandı. Do ̆grulanan metabolitlerin konsantrasyonları kar ̧sıla ̧stırıldı.Bu çalı ̧sma, KML'nin ALL'ye blastik transformasyonu üzerine odaklanan ilk me-tabolomik çalı ̧smadır. Bu çalı ̧smanın sonuçları, daha sonraki çalı ̧smalarda CML veALL'yi ayırt eden paternler tanımlamak için kullanılabilir.
İngilizce Başlık : Akut lenfoblastik lösemi (ALL) ve kronik miyeloid lösemi (KML) hücre hatları arasındaki metabolitvaryasyonun triple kuadrupol LC-MS ile değerlendirilmesi
İngilizce Özet :
Hematologic cancers have two origins: myeloid and lymphoid. While lymphatic leukemia, originate from the lymphoid cell line, acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) originate from the myeloid cell line.CML is granulocyte cancer and in this disease, as well as granulocytes, the number of cells that cause blood clotting, which are called platelets, may increase in the blood. In CML, a non-hereditary genetic abnormality, Philadelphia chromosome, where a structural change occurs in chromosome 22, is seen in blood cells. Acute lymphoblastic leukemia (ALL), on the other hand, is caused by abnormally uncontrolled and excessive proliferation of lymphoblasts. ALL is responsible for 80% of childhood leukemia and is common between 3-7 years of age. It can also be seen in adults and accounts for 20% of all adult leukemia. Interestingly, it was recorded thatCML in its blast phase can turn into acute leukemia. It is not known which mutationscause this conversion.Since all leukemia subtypes stem from the bone marrow, the gold standard for thev diagnosis of leukemia types is genetic testing via invasive bone marrow biopsy, butit has a healing process and can have psychological impacts, especially on children,thus recently, metabolomics, non-invasive and fast methods that can help in earlydiagnosis are being studied in leukemia. The cells obtained via bone marrow biopsyare examined for chromosomal abnormalities with cytogenetics analysis.In this study, the metabolic differences of Jurkat (ALL) and K562 (CML-BP) cell lines were aimed to be evaluated using HPLC-MS. Quantitative and quasi-quantitative studies were held to have an idea of the amounts of metabolites in each cell line. After measuring the concentrations of lactic acid and citric acid with the use of their authentic standards, a mass screening was performed on both cell lines, and it was seen that the metabolisms that are mainly affected during the conversion are tyrosine, arginine and proline, and glutathione metabolisms. Thus, the existence of indicator metabolites of these related pathways were scanned. Intensities of the confirmed metabolites were compared. This study is the first metabolomics study that focuses on the blastic transformation of CML to ALL. Results of this study can be used in further studies to define a dif-ferentiating pattern for CML and ALL.
9
Acute myeloid leukemia in adults
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Treatment Options in Oncology
Yazar(lar) :
Larry D. Cripe , Stuart Hinton
Konu :
Pharmacology (medical), Oncology
Yıl :
2000
Acute myeloid leukemia in adults The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m2 as a continuous intravenous infusion over 24 hours for 7 days) and Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible. Current Treatment Options in Oncology Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m2 as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, darubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.
DOI : 10.1007/s11864-000-0011-3
Anahtar Kelimeler : Overall Survival, Acute Myeloid Leukemia, Cytarabine, Daunorubicin, Main Drug Interaction
ISSN: 1527-2729 1534-6277
Sayı: 1
Cilt: 1
Sayfa: 9-17
Sınıflandırma :
10
Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Supportive Care in Cancer
Yazar(lar) :
Siyang Li , Jeffrey Traubici , Marie-Chantal Ethier , Biljana Gillmeister , Sarah Alexander , Adam Gassas , Lillian Sung
Konu :
Oncology
Yıl :
2011
Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia To describe symptoms, diagnostic features, treatments, and outcomes of pneumatosis intestinalis (PI) in pediatric patients being treated for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). PI is uncommon in children with ALL or AML. Ultrasound is less sensitive than plain radiographs for diagnosis. Children Acute lymphoblastic leukemia Acute myeloid leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
To describe symptoms, diagnostic features, treatments, and outcomes of pneumatosis intestinalis (PI) in pediatric patients being treated for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This retrospective chart review included 514 patients ≤18 years of age diagnosed with ALL or AML between January 1999 and December 2007. PI episodes were identified by radiology report reviews. Twenty patients with ALL and four patients with AML presented 31 PI episodes. The median time between diagnoses of leukemia and PI was 1.0 month (interquartile range 0.8–6.4 months). Plain radiographs diagnosed all PI episodes. Computerized tomography (CT) and ultrasound were performed in 6 and 13 episodes, respectively. All CT and three ultrasounds demonstrated PI. Thirty episodes occurred exclusively in the colon, most commonly in the ascending (n = 26) and transverse (n = 18) segments. Treatment included complete bowel rest in 27 (87.1%) and intravenous broad-spectrum antibiotics in 29 (93.5%). One case required colectomy. Two episodes were untreated. There were no fatalities associated with PI. PI is uncommon in children with ALL or AML. Ultrasound is less sensitive than plain radiographs for diagnosis. PI occurred almost exclusively in the colon. With conservative management, most patients had excellent outcome.
DOI : 10.1007/s00520-011-1088-x
Anahtar Kelimeler : Pneumatosis intestinalis, Children, Acute lymphoblastic leukemia, Acute myeloid leukemia
ISSN: 0941-4355 1433-7339
Sayı: 2
Cilt: 20
Sayfa: 343-347
11
Convolution Neural Network Models for Acute Leukemia Diagnosis
Konferans Bildirileri

Konferans Bildirileri
Kaynak :
IEEE Xplore
Yazar(lar) :
Maila Claro , Luis Vogado , Rodrigo Veras , Andre Santana , Joao Tavares , Justino Santos , Vinicius Machado
Konu :
Computing and Processing, Signal Processing and Analysis
Yıl :
2020
Convolution Neural Network Models for Acute Leukemia Diagnosis Acute leukemia is a cancer-related to a bone marrow abnormality. It is more common in children and young adults. This type of leukemia generates unusual cell growth in a short period, requiring a quick start of treatment. Acute Lymphoid Leukemia (ALL) and Acute Myeloid Leukemia (AML) are the main responsible for deaths caused by this cancer. Computing and Processing,Signal Processing and Analysis 2020 International Conference on Systems, Signals and Image Processing (IWSSIP) Acute Leukemia diagnosis Acute Lymphoid Leukemia Acute Myeloid Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute leukemia is a cancer-related to a bone marrow abnormality. It is more common in children and young adults. This type of leukemia generates unusual cell growth in a short period, requiring a quick start of treatment. Acute Lymphoid Leukemia (ALL) and Acute Myeloid Leukemia (AML) are the main responsible for deaths caused by this cancer. The classification of these two leukemia types on blood slide images is a vital process of and automatic system that can assist doctors in the selection of appropriate treatment. This work presents a convolutional neural networks (CNNs) architecture capable of differentiating blood slides with ALL, AML and Healthy Blood Slides (HBS). The experiments were performed using 16 datasets with 2,415 images, and the accuracy of 97.18% and a precision of 97.23% were achieved. The proposed model results were compared with the results obtained by the state of the art methods, including also based on CNNs.
DOI : 10.1109/iwssip48289.2020.9145406
Anahtar Kelimeler : Computer architecture, Blood, Microprocessors, Support vector machines, Training, Computational modeling, Convolution, blood, bone, cancer, cellular biophysics, convolutional neural nets, medical image processing, neural net architecture, patient diagnosis, patient treatment, Acute Leukemia diagnosis, cancer, bone marrow abnormality, young adults, unusual cell growth, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, AML, leukemia types, blood slide images, automatic system, convolutional neural networks architecture, healthy blood slides, leukemia diagnosis, convolutional neural network, computer aided diagnosis
12
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
memo - Magazine of European Medical Oncology
Yazar(lar) :
Mirella Ampatzidou , Charikleia Kelaidi , Michael N. Dworzak , Sophia Polychronopoulou
Konu :
Oncology, Hematology
Yıl :
2017
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia At the therapeutic intersection between children and older adults, the treatment of adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) poses unique challenges due to their dismal outcome. Intensification of supportive care while maintaining treatment intensity could further improve outcomes of AYAs with leukemia. Adolescents and young adults (AYAs) Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
At the therapeutic intersection between children and older adults, the treatment of adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) poses unique challenges due to their dismal outcome. In this brief review, we report on the biological features, clinical characteristics and treatment results of a pediatric and AYAs cohort of ALL and AML, treated in our department over a 15-year period. Additionally, we review the recent insights into disease biology, clinical, cytogenetic and molecular characteristics and differences between pediatric patients and AYAs with ALL and AML. In AYAs with ALL, most retrospective trials demonstrated a benefit of pediatric inspired regimens versus adult protocols. Translating the promising pediatric results to the AYAs subgroup, these patients can be successfully treated with risk-adjusted and minimal residual disease (MRD)-guided intensified chemotherapy, with survival rates that can surpass 70%. In AYAs the AML disease is genetically positioned more on the side of adult AML than on that of younger children, but also carries its own specific abnormalities, such as NUP98-NSD1. Toxicity may complicate all phases of treatment (induction and post-induction chemotherapy, hematopoietic stem cell transplantation-HSCT) and accounts for increased mortality, which counterbalances reduced cumulative incidence of relapse (CIR), in comparison with younger children. Intensification of supportive care while maintaining treatment intensity could further improve outcomes of AYAs with leukemia. Cooperative efforts between pediatric and adult hematologists are needed in order to further improve survival of AYAs with ALL and AML.
DOI : 10.1007/s12254-017-0345-1
Anahtar Kelimeler : Adolescents and young adults (AYAs), Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Pediatric hematology-oncology
ISSN: 1865-5041 1865-5076
Sayı: 1
Cilt: 11
Sayfa: 47-53
13
Highly refractory acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Wiener Klinische Wochenschrift
Yazar(lar) :
Wolfgang Füreder , Martin Filipits , Wolfgang R. Sperr , Birgit Kainz , Ulrich Jäger , Christa Fonatsch , Ilse Schwarzinger , Oskar A. Haas , Robert Pirker , Klaus Lechner
Konu :
General Medicine
Yıl :
2004
Highly refractory acute myeloid leukemia In this study we evaluated 103 patients suffering from acute myeloid leukemia (AML) who did not respond to induction chemotherapy and defined a subgroup of patients with highly refractory disease characterized by a persistence of more than 1G/L blast cells in the peripheral blood between days 12 and Four had de novo AML and three secondary AML. Leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
In this study we evaluated 103 patients suffering from acute myeloid leukemia (AML) who did not respond to induction chemotherapy and defined a subgroup of patients with highly refractory disease characterized by a persistence of more than 1G/L blast cells in the peripheral blood between days 12 and 16 of the first induction cycle. Only seven patients (one female, six males) met these criteria. Their median age was 65 years (range 41–82 years). Four had de novo AML and three secondary AML. Cytogenetic analysis was performed in six patients: complex aberrations were detected in four patients and, unexpectedly, normal karyotypes were found in the other two. Analysis of multidrug-resistance factors revealed high co-expression of P-glycoprotein (P-gp) and lung resistance protein (LRP) in all four patients with highly refractory disease tested a finding in only 6% of patients with refractory disease and 3% of patients who achieved complete remission (CR) of disease. Furthermore, patients with highly refractory AML had substantially higher leukocyte counts than patients with refractory AML or CR, although this was not significant statistically. Overall, patients with highly refractory AML are characterized by a high incidence of complex cytogenetic aberrations and marked expression of drug transporters.
DOI : 10.1007/bf03217710
Anahtar Kelimeler : Leukemia, refractory, multidrug resistance, cytogenetics
ISSN: 0043-5325 1613-7671
Sayı: 15-16
Cilt: 116
Sayfa: 561-564
Sınıflandırma :
14
Immunotherapy in acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Cancer
Yazar(lar) :
Dolores A. Grosso , Rosemary C. Hess , Mark A. Weiss
Konu :
Cancer Research, Oncology
Yıl :
2015
Immunotherapy in acute myeloid leukemia Despite the remarkable progress made in some leukemias such as CML and CLL, cytotoxic treatment for AML remains essentially unchanged over the last 4 decades Allogeneic HSCT exploits major and minor histocompatibility differences between the donor and recipient in order to recognize and eradicate malignancy. the treatment of this disease.
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Despite the remarkable progress made in some leukemias such as CML and CLL, cytotoxic treatment for AML remains essentially unchanged over the last 4 decades. Several lines of evidence, including the graft versus leukemia effect associated with allogeneic hematopoietic stem cell transplantation (HSCT), suggest that immunotherapy is an active modality in AML. Given the lack of progress for chemotherapy in this disease, many novel immunologic treatment approaches have been explored. The goals of non‐transplant‐based immune approaches have largely consisted of the stimulation or restoration of endogenous immune responses or the targeting of specific tumor antigens by immune cells. These strategies have been associated with less toxicity than allogeneic HSCT but typically have inferior efficacy. Allogeneic HSCT exploits major and minor histocompatibility differences between the donor and recipient in order to recognize and eradicate malignancy. With the recognition that the immune system itself provides a basis for treating AML, immunotherapy continues to be an attractive modality to exploit in the treatment of this disease. Cancer 2015;121:2689‐2704. © 2015 American Cancer Society
DOI : 10.1002/cncr.29378
ISSN: 0008-543X
Sayı: 16
Cilt: 121
Sayfa: 2689-2704
Sınıflandırma :
Hematoloji %100
15
Acute myeloid leukemia: Epidemiology and etiology
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Cancer
Yazar(lar) :
Barbara Deschler , Michael Lübbert
Konu :
Cancer Research, Oncology
Yıl :
2006
Acute myeloid leukemia: Epidemiology and etiology Acute myeloid leukemias (AMLs) are infrequent, yet highly malignant neoplasms responsible for a large number of cancer‐related deaths. It continuously shows 2 peaks in occurrence in early childhood and later adulthood. inversion of chromosome 16, and acute promyelocytic leukemia with the translocation (15;17)).
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute myeloid leukemias (AMLs) are infrequent, yet highly malignant neoplasms responsible for a large number of cancer‐related deaths. The incidence has been near stable over the last years. It continuously shows 2 peaks in occurrence in early childhood and later adulthood. With an incidence of 3.7 per 100,000 persons and an age‐dependent mortality of 2.7 to nearly 18 per 100,000 persons, there is a rising awareness in the Western world of AML's special attributes resulting from an ever‐aging population. To objectively describe epidemiologic data on this patient population, recent publications were evaluated to make transparent the current trends and facts. A review of the literature is presented, reflecting highlights of current research with respect to AML etiology. To estimate outcome and discuss informed treatment decisions with AML patients of different age groups and different biologic risk categories, it is mandatory to consider that the outcome results reported in clinical trials were until now heavily biased toward younger patients, whereas the overall dismal prognosis documented in population‐based studies most likely reflects the exclusion of older patients from aggressive treatment. The etiology for most cases of AML is unclear, but a growing knowledge concerning leukemogenenic agents within chemotherapy regimens for other malignancies is already available. This includes specific associations of the most frequent balanced translocations in AML, including the “good‐risk” abnormalities comprised by the core binding factor leukemias (i.e., AML with the translocation (8;21) and inversion of chromosome 16, and acute promyelocytic leukemia with the translocation (15;17)). In contrast to these genetic alterations, epigenetic lesions, e.g., promoter silencing by hypermethylation of the p15/INK4b and other genes, are increasingly recognized as important in the pathogenesis of AML. Cancer 2006. © 2006 American Cancer Society.
DOI : 10.1002/cncr.22233
ISSN: 0008-543X
Sayı: 9
Cilt: 107
Sayfa: 2099-2107
16
Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
International Journal of Hematology
Yazar(lar) :
Hiroyoshi Takahashi , Katsuyoshi Koh , Motohiro Kato , Hiroshi Kishimoto , Eiji Oguma , Ryoji Hanada
Konu :
Hematology
Yıl :
2012
Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase We report the case of a 14-year-old female with acute myeloid leukemia (AML) and myeloid sarcomas (MS) in the anterior mediastinum and around numerous HLA-DR, but negative for CD34 and CD56. Aggressive MS in childhood is rare and refractory to existing AML chemotherapy. Acute myeloid leukemia Myeloid sarcoma
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
We report the case of a 14-year-old female with acute myeloid leukemia (AML) and myeloid sarcomas (MS) in the anterior mediastinum and around numerous bones. Laboratory tests showed a white blood cell count of 4.0 × 109/l with 7.0 % blasts. Computed tomography revealed a mediastinal mass and pleural effusion; pleural effusion cytology was negative for malignant cells. In addition, disseminated intravascular coagulation (DIC) was present. Following DIC therapy, thoracoscopic and bone marrow biopsies were performed. Immunostaining and surface marker analysis revealed that the blast cells were positive for cytoplasmic myeloperoxidase, CD4, CD7, CD33, CD44, CD117, and HLA-DR, but negative for CD34 and CD56. Karyotype was normal. MS associated with AML was diagnosed. Multidrug chemotherapy for AML was completely ineffective, and MS continued to progress. Immunohistochemistry revealed that the blasts were negative for asparagine synthetase (AS); therefore, chemotherapy including l-asparaginase was initiated. After the first administration of l-asparaginase, the patient’s condition improved; however, she subsequently developed tumor lysis syndrome and sepsis, which eventually led to death. Aggressive MS in childhood is rare and refractory to existing AML chemotherapy. Chemotherapy including l-asparaginase may prove to be effective in such cases, especially those in which blast cells show negative AS expression.
DOI : 10.1007/s12185-012-1111-0
Anahtar Kelimeler : Acute myeloid leukemia, Myeloid sarcoma, Mediastinal tumor, l-asparaginase, l, CD44
ISSN: 0925-5710 1865-3774
Sayı: 1
Cilt: 96
Sayfa: 136-140
17
Cytogenetics in acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Oncology Reports
Yazar(lar) :
Claudia Schoch , Torsten Haferlach
Konu :
Oncology
Yıl :
2002
Cytogenetics in acute myeloid leukemia Cytogenetic analysis is the most important diagnostic tool for determining prognosis in acute myeloid leukemia (AML). The identification of specific chromosomal abnormalities and their correlation with cytomorphologic features, immunophenotype, and clinical outcome have clinical context, and the new World Health Organization classification of AML uses cytogenetic abnormalities as a major criterion. Acute Myeloid Leukemia Acute Myelogenous Leukemia Acute Myeloid Leukemia Patient
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Cytogenetic analysis is the most important diagnostic tool for determining prognosis in acute myeloid leukemia (AML). In the majority of patients with AML, acquired clonal chromosome aberrations can be observed. Numerous recurrent karyotype abnormalities have been discovered in AML. These findings on the chromosomal level have paved the way for molecular studies that have identified genes involved in the process of leukemogenesis. The identification of specific chromosomal abnormalities and their correlation with cytomorphologic features, immunophenotype, and clinical outcome have led to a new understanding of AML as a heterogeneous group of distinct biologic entities. The importance of cytogenetic findings in AML for classification and for the understanding of pathogenetic mechanisms is increasingly appreciated in the clinical context, and the new World Health Organization classification of AML uses cytogenetic abnormalities as a major criterion.
DOI : 10.1007/s11912-002-0032-0
Anahtar Kelimeler : Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Acute Myelogenous Leukemia, Chromosome Aberration, Acute Myeloid Leukemia Patient
ISSN: 1523-3790 1534-6269
Sayı: 5
Cilt: 4
Sayfa: 390-397
18
Familial myelodysplastic syndrome/acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Best Practice & Research Clinical Haematology
Yayıncı:
Elsevier
Yazar(lar) :
Jane E. Churpek
Yıl :
2017
Familial myelodysplastic syndrome/acute myeloid leukemia A growing number of inherited genetic loci that contribute to myelodysplastic syndrome/ acute myeloid leukemia (MDS/AML) development in both children International collaborative efforts to store germline tissue, document family histories, and pool data are essential to progress in diagnosing and treating both hereditary and sporadic forms of MDS/AML. Acute myeloid leukemia Hereditary myeloid malignancy syndromes
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
A growing number of inherited genetic loci that contribute to myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) development in both children as well as adults are rapidly being identified. In recognition of the clinical impact of this emerging field, the World Health Organization, National Comprehensive Cancer Network, and European LeukemiaNet have all added consideration of inherited predisposition to MDS/AML classification and management. Study of these disorders is providing unique insight into the biology of both sporadic and familial MDS/AML. International collaborative efforts to store germline tissue, document family histories, and pool data are essential to progress in diagnosing and treating both hereditary and sporadic forms of MDS/AML.
DOI : 10.1016/j.beha.2017.10.002
Anahtar Kelimeler : Acute myeloid leukemia, AML, Inherited, Genetics, Hereditary myeloid malignancy syndromes, MDS, Myelodysplastic syndromes, Predisposition
ISSN: 1521-6926
Sayı: 4
Cilt: 30
Sayfa: 287-289
19
Acute myeloid leukemia in manitoba
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Cancer
Yazar(lar) :
Eric J. Bow , Marilyn G. Kilpartick , Barbara A. Scott , Jennifer J. Clinich , Mary S. Cheang
Konu :
Cancer Research, Oncology
Yıl :
1994
Acute myeloid leukemia in manitoba To the authors' knowledge, the natural history of myelosuppression and infectious complications associated with the use of standard cytarabine (ARA‐C) plus daunorubicin (“7 + 3”) remission‐induction therapy for adult acute myeloid leukemia (AML) and high dose ARA‐C (HDARA‐C) consolidation has not been
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Background. To the authors' knowledge, the natural history of myelosuppression and infectious complications associated with the use of standard cytarabine (ARA‐C) plus daunorubicin (“7 + 3”) remission‐induction therapy for adult acute myeloid leukemia (AML) and high dose ARA‐C (HDARA‐C) consolidation has not been described completely.
DOI : 10.1002/1097-0142(19940701)74:1<52::aid-cncr2820740110>3.0.co;2-g
ISSN: 0008-543X
Sayı: 1
Cilt: 74
Sayfa: 52-60
20
Epidemiology of childhood acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Pediatric Blood & Cancer
Yazar(lar) :
Susan E. Puumala , Julie A. Ross , Richard Aplenc , Logan G. Spector
Konu :
Pediatrics, Perinatology, and Child Health, Oncology, Hematology
Yıl :
2013
Epidemiology of childhood acute myeloid leukemia Although leukemia is the most common childhood cancer diagnosis, the subtype, acute myeloid leukemia (AML), is less common and fewer etiologic studies We searched the literature using PubMed for articles on childhood AML and reviewed 180 articles. Thorough analysis of genetic and epigenetic factors is missing from this literature and methodological issues are unresolved. Pediatrics, Perinatology, and Child Health,Oncology,Hematology
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Although leukemia is the most common childhood cancer diagnosis, the subtype, acute myeloid leukemia (AML), is less common and fewer etiologic studies exist. This review summarizes the major risk factors for AML. We searched the literature using PubMed for articles on childhood AML and reviewed 180 articles. While few risk factors are definitive, we identified several with consistent evidence of a possible effect. Thorough analysis of genetic and epigenetic factors is missing from this literature and methodological issues are unresolved. Future studies should more closely examine causal mechanisms, improve exposure measurement, and include analysis using genetic and epigenetic factors. Pediatr Blood Cancer 2013; 60: 728–733. © 2013 Wiley Periodicals, Inc.
DOI : 10.1002/pbc.24464
ISSN: 1545-5009
Sayı: 5
Cilt: 60
Sayfa: 728-733
21
ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Reviews in Clinical and Experimental Hematology
Yazar(lar) :
Thomas Buchner , Wolfgang Hiddemann , Wolfgang Berdel , Bernhard Wormann , Claudia Schoch , Helmut Loffler , Torsten Haferlach , Andrea Schumacher , Peter Staib , Leopold Balleisen , Andreas Gruneisen , Herbert Rasche , Carlo Aul , Axel Heyll , Eva Lengfelder , Wolf-Dieter Ludwig , Georg Maschmeyer , Hartmut Eimermacher , Jochen Karow , Norbert Frickhofen , Wolf-Dietrich Hirschmann , Maria-Cristina Sauerland
Konu :
Hematology
Yıl :
2002
ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60 Undertreatment of older patients with acute myeloid leukemia (AML) can explain, in part, their inferior outcome when compared to that of younger patients and for the duration of postremission treatment. A questionnaire study in patients with AML showed that, according to patients’ self‐assessment, intensive and prolonged treatment did not result in a diminished Reviews in Clinical and Experimental Hematology
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Undertreatment of older patients with acute myeloid leukemia (AML) can explain, in part, their inferior outcome when compared to that of younger patients. In agreement with the benefit seen by patients under age 60 from high‐dose cytosine arabinoside (Ara‐C), there are dose effects in the over 60s, in particular for daunorubicin, in induction treatment and for the duration of postremission treatment. The use of these effects can partly overcome the mostly unfavorable disease biology in older age AML, as expressed by the absence of favorable and the over‐representation of adverse chromosomal abnormalities as well as the expression of drug resistance. We recommend an adequate dosage of 60 mg/m2 daunorubicin on 3 days in combination with standard dose Ara‐C and 6‐thioguanine given for induction and consolidation, and followed by a prolonged monthly maintenance chemotherapy for at least 1 year's duration. Further improvements in supportive care may help to deliver additional antileukemic cytotoxicity. As a novel approach, nonmyeloablative preparative regimens may open up the possibility of allogeneic transplantation for older patients with AML. Other new options like multidrug resistance modulators, antibody targeted therapies and molecular targeting are under clinical investigation. A questionnaire study in patients with AML showed that, according to patients’ self‐assessment, intensive and prolonged treatment did not result in a diminished quality of life. This finding did not vary by age, under or over 60 years. As the median age in this disease is more than 60 years, the adequate management of AML in older patients remains the major challenge.
DOI : 10.1046/j.1468-0734.2002.00059.x
ISSN: 1127-0020
Sayı: 1
Cilt: 6
Sayfa: 46-59
22
Maintenance treatment in acute myeloid leukemia
Kitap Bölümü

Kitap Bölümü
Kaynak :
Wiley Online Library
Dergi:
Evidence-Based Pediatric Oncology
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Ananth Shankar
Yıl :
2013
Maintenance treatment in acute myeloid leukemia The use of postremission low‐dose maintenance treatment (MT) in childhood acute myeloid leukemia (AML) has yielded mixed results. The studies by Perel et al. and Wells et al. suggest that MT does not appear to improve overall survival (OS). The acute promyelocytic leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL.
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The use of postremission low‐dose maintenance treatment (MT) in childhood acute myeloid leukemia (AML) has yielded mixed results. This chapter provides a summary of previous studies. The studies by Perel et al. and Wells et al. suggest that MT does not appear to improve overall survival (OS). The acute promyelocytic leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL. A later study, the GIMEMA‐AIEOPAIDA trial, also evaluated the benefit of MT in childhood AML. MT with ATRA combined with CT improved survival outcome in children with APL although no conclusion can be drawn on the advantage of MT in APL due to early closure of the control arm.
DOI : 10.1002/9781118625309.ch15
ISBN:9780470659649
Sayfa: 137-140
23
Older adults with acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Oncology Reports
Yazar(lar) :
Mikkael A. Sekeres , Richard Stone
Konu :
Oncology
Yıl :
2002
Older adults with acute myeloid leukemia Acute myeloid leukemia (AML) occurs most frequently in older adults, with a median age range from 65 to 70 years. Both the disease and its treatment are distinct from their counterparts in young patients. Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches, and Acute Myeloid Leukemia Acute Myelogenous Leukemia Acute Myeloid Leukemia Patient
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute myeloid leukemia (AML) occurs most frequently in older adults, with a median age range from 65 to 70 years. Both the disease and its treatment are distinct from their counterparts in young patients. Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches, and discuss therapeutic strategies in development.
DOI : 10.1007/s11912-002-0034-y
Anahtar Kelimeler : Acute Myeloid Leukemia, Clin Oncol, Acute Myelogenous Leukemia, Acute Myeloid Leukemia Patient, Idarubicin
ISSN: 1523-3790 1534-6269
Sayı: 5
Cilt: 4
Sayfa: 403-409
24
Acute myeloid leukemia in infants: biology and treatment
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Pediatrics
Yazar(lar) :
Riccardo eMasetti , Francesca eVendemini , Daniele eZama , Carlotta eBiagi , Andrea ePession , Franco eLocatelli , Franco eLocatelli
Yıl :
2015
Acute myeloid leukemia in infants: biology and treatment Children aged 0–2 years (i.e. infants) with acute myeloid leukemia (AML) are a peculiar subgroup of patients in the childhood AML scenario. Remarkable improvements have been achieved over the last 2 decades in the treatment of these patients and their outcome is becoming superimposable to that Treatment results and toxicity data reported by major collaborative groups are also summarized and compared. acute myeloid leukemia (AML) Treatment results
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Children aged 0–2 years (i.e. infants) with acute myeloid leukemia (AML) are a peculiar subgroup of patients in the childhood AML scenario. They present with distinctive biological and clinical characteristics, including a high prevalence of prognostically unfavorable risk factors and an increased susceptibility to therapy-related toxicity. Remarkable improvements have been achieved over the last 2 decades in the treatment of these patients and their outcome is becoming superimposable to that of the older age groups. In this review, we will focus on peculiarities of this young subgroup of children with AML, describing their clinical presentation, the biology of disease and factors influencing outcome. Treatment results and toxicity data reported by major collaborative groups are also summarized and compared.
DOI : 10.3389/fped.2015.00037
Anahtar Kelimeler : Hematopoietic Stem Cell Transplantation, Toxicity, infants, acute myeloid leukemia (AML), prognostic factors, Treatment results
ISSN: 2296-2360
Cilt: 3
Sınıflandırma :
25
Acute Myeloid Leukemia with Normal Cytogenetics
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Current Oncology Reports
Yazar(lar) :
Raya Mawad , Elihu H. Estey
Konu :
Oncology
Yıl :
2012
Acute Myeloid Leukemia with Normal Cytogenetics Acute myeloid leukemia (AML) is proving to be a heterogeneous disease process that is driven by various genetic mutations and aberrant protein expression As we learn more, we hope to further categorize patients with normal karyotype AML into discrete risk categories that will help in treatment decision making and further elucidate the necessity for hematopoietic cell transplantation. Acute myeloid leukemia
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute myeloid leukemia (AML) is proving to be a heterogeneous disease process that is driven by various genetic mutations and aberrant protein expression. As our population ages, the incidence of AML is likely to increase, with approximately a third of adult cases categorized with normal cytogenetics. Advances in technology are now allowing us to explore the genetic expression and protein transcription patterns of AML, providing more information that must find its place in the prognosis and the therapeutic algorithm of this disease. As we learn more, we hope to further categorize patients with normal karyotype AML into discrete risk categories that will help in treatment decision making and further elucidate the necessity for hematopoietic cell transplantation. However, at this time, many of the identified mutations and expression patterns are still experimental, requiring further analysis to determine their exact role in AML.
DOI : 10.1007/s11912-012-0252-x
Anahtar Kelimeler : Acute myeloid leukemia, AML, Normal cytogenetics, Normal karyotype, Intermediate risk
ISSN: 1523-3790 1534-6269
Sayı: 5
Cilt: 14
Sayfa: 359-368
26
Cytogenetics of pediatric acute myeloid leukemia
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
European Journal of Haematology
Yazar(lar) :
Kalliopi N. Manola
Konu :
Hematology, General Medicine
Yıl :
2009
Cytogenetics of pediatric acute myeloid leukemia Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease accounting for 15–20% of all childhood acute leukemias, while it is treatment selection in childhood AML. the variable treatment modalities used in different study groups.
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease accounting for 15–20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. This article focuses on the significance of cytogenetic analysis in pediatric AML supporting the importance of cytogenetic analysis in the pathogenesis, diagnosis, prognosis, follow‐up and treatment selection in childhood AML. It reviews in detail the types and frequencies of most common chromosomal aberrations, their molecular background, their correlation with French American British (FAB) subtypes and age distribution and their prognostic relevance. It also summarizes some less frequent or rare chromosome aberrations in which the prognostic classification has not been determined yet owning to the small number of patients and the variable treatment modalities used in different study groups. Furthermore, it discusses the association of specific chromosome rearrangements with prenatal exposure to carcinogenic agents or therapeutic agents and highlights the ongoing and future research on pediatric AML in the evolving field of Cytogenetics.
DOI : 10.1111/j.1600-0609.2009.01308.x
ISSN: 0902-4441
Sayı: 5
Cilt: 83
Sayfa: 391-405
27
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Chinese Medical Journal
Yazar(lar) :
Meng-Ge Yu , Hu-Yong Zheng
Yıl :
2017
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment Objective: Leukemia is the most common pediatric malignancy and a major cause of morbidity and mortality in children. Among all subtypes, a lack of consensus exists regarding the diagnosis and treatment of acute myeloid leukemia (AML). Results: We described clonal evolution and how it changes our view on leukemogenesis, treatment responses, and disease relapse. Acute Myeloid Leukemia
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Objective: Leukemia is the most common pediatric malignancy and a major cause of morbidity and mortality in children. Among all subtypes, a lack of consensus exists regarding the diagnosis and treatment of acute myeloid leukemia (AML). Patient survival rates have remained modest for the past three decades in AML. Recently, targeted therapy has emerged as a promising treatment. Data Sources: We searched the PubMed database for recently published research papers on diagnostic development, target therapy, and other novel therapies of AML. Clinical trial information was obtained from ClinicalTrials.gov. For the major purpose of this review that is to outline the latest therapeutic development of AML, we only listed the ongoing clinical trials for reference. However, the published results of complete clinical trials were also mentioned. Study Selection: This article reviewed the latest developments related to the diagnosis and treatment of AML. In the first portion, we provided some novel insights on the molecular basis of AML, as well as provided an update on the classification of AML. In the second portion, we summarized the results of research on potential molecular therapeutic agents including monoclonal antibodies, tyrosine kinase/Fms-like tyrosine kinase 3 (FLT3) inhibitors, epigenetic/demethylating agents, and cellular therapeutic agents. We will also highlight ongoing research and clinical trials in pediatric AML. Results: We described clonal evolution and how it changes our view on leukemogenesis, treatment responses, and disease relapse. Pediatric-specific genomic mapping was discussed with a novel diagnostic method highlighted. In the later portion of this review, we summarized the researches on potential molecular therapeutic agents including monoclonal antibodies, tyrosine kinase/FLT3 inhibitors, epigenetic/demethylating agents, and cellular therapeutic agents. Conclusion: Gene sequencing techniques should set the basis for next-generation diagnostic methods of AML, and target therapy should be the focus of future clinical research in the exploration of therapeutic possibilities.
DOI : 10.4103/0366-6999.198004
Anahtar Kelimeler : Acute Myeloid Leukemia, Advancements, Diagnosis, Target Therapy
Cilt: 130
Sayı: 2
Sayfa: 211 - 218
Sınıflandırma :
Hematoloji %100

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler